Legend Biotech (NASDAQ:LEGN) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc..
Legend Biotech (LEGN) Valuation Check After Barclays Update And 2026 Profitability Targets [Yahoo! Finance]
FDA Guidance on MRD Negativity Bodes Well for Legend Biotech (LEGN) [Yahoo! Finance]
Legend Biotech (NASDAQ:LEGN) was downgraded by analysts at Rothschild & Co Redburn from a "buy" rating to a "neutral" rating. They now have a $24.00 price target on the stock.
Legend Biotech (LEGN) Shakes Up Board [Yahoo! Finance]